.webp?width=217&height=60&name=Screenpoint-Med%20(1).webp "Screen Point Medical")
MASAI RCT: 12% reduction in interval cancer rate using Transpara
%20(1).png)
MASAI RCT: 12% reduction in interval cancer rate using Transpara
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
.png)
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
ScreenPoint Medical Enables Transpara® Breast AI within Precision Imaging Network, part of Microsoft for Healthcare
.png)
ScreenPoint Medical Enables Transpara® Breast AI within Precision Imaging Network, part of Microsoft for Healthcare
ScreenPoint Medical Acquires Biomediq A/S to Expand Breast Cancer Risk Assessment Capabilities
ScreenPoint Medical Acquires Biomediq A/S to Expand Breast Cancer Risk Assessment Capabilities
Deal brings enhanced capabilities for ScreenPoint’s industry-leading Transpara Breast AI.
January 08, 2025